New treatment, which allows previously topical drug to be administered intravenously, is ‘a game-changer’ in the battle against antibiotic-resistant bacteria. It could have a significant impact on the morbidity rate for pandemics such as COVID-19.
Available Technologies
The future is here
Yissum is the Technology Transfer company of The Hebrew University of Jerusalem. Our mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges.
We are leaders in innovation and experts in technology and evaluation acquisition strategies. Together with Hebrew University’s top researchers, Yissum is bridging breakthrough academic research with scientific and commercial applications.
HU Researchers Submit Proposals to IIA to Investigate Covid-19 Treatments
Researchers at The Hebrew University of Jerusalem as well as several Yissum start-up companies are exploring a variety of methods to combat the COVID-19 virus, through investigations into AI drug discovery, biochemical detection tools, and diagnostic capabilities. The IIA awarded over 40% of its academic grants to HU reseachers
Leading Hebrew U Prof. Says You are Unlikely to Die from COVID-19
Isaiah (Shy) Arkin is a professor of Structural Biochemistry at the Hebrew University of Jerusalem, whose research, among other achievements, has shed new light on the inner workings of viruses. The Times of Israel spoke to him to try to understand more about the coronavirus, how it compares to other viruses, how its spread might stop or be stopped, and how worried humankind should be about it.
HU Reseachers Collaborate With Weizmann Experts To Predict COVID-19 Outbreak Zones
Researchers from the Hebrew University, the Weizmann institute of Science and the Israel Health Ministry have developed a method to help identify, monitor and possibly predict future coronavirus outbreak zones.
Success Stories
